CN101384618A - 癌中capcna蛋白-蛋白相互作用的肽基抑制 - Google Patents

癌中capcna蛋白-蛋白相互作用的肽基抑制 Download PDF

Info

Publication number
CN101384618A
CN101384618A CNA2007800052894A CN200780005289A CN101384618A CN 101384618 A CN101384618 A CN 101384618A CN A2007800052894 A CNA2007800052894 A CN A2007800052894A CN 200780005289 A CN200780005289 A CN 200780005289A CN 101384618 A CN101384618 A CN 101384618A
Authority
CN
China
Prior art keywords
capcna
cancer
composition
peptide
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800052894A
Other languages
English (en)
Chinese (zh)
Inventor
R·J·希基
L·H·马尔卡斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Indiana University Research and Technology Corp
Original Assignee
Indiana University Research and Technology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indiana University Research and Technology Corp filed Critical Indiana University Research and Technology Corp
Publication of CN101384618A publication Critical patent/CN101384618A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CNA2007800052894A 2006-02-17 2007-02-16 癌中capcna蛋白-蛋白相互作用的肽基抑制 Pending CN101384618A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74331306P 2006-02-17 2006-02-17
US60/743,313 2006-02-17

Publications (1)

Publication Number Publication Date
CN101384618A true CN101384618A (zh) 2009-03-11

Family

ID=38235155

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2007800052894A Pending CN101384618A (zh) 2006-02-17 2007-02-16 癌中capcna蛋白-蛋白相互作用的肽基抑制

Country Status (9)

Country Link
US (3) US8653039B2 (enExample)
EP (1) EP1989225A2 (enExample)
JP (1) JP2009527498A (enExample)
CN (1) CN101384618A (enExample)
AU (1) AU2007217037A1 (enExample)
BR (1) BRPI0707948A2 (enExample)
CA (1) CA2638866C (enExample)
EA (1) EA200801847A1 (enExample)
WO (1) WO2007098415A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107404876A (zh) * 2015-04-10 2017-11-28 雷尔有限责任公司 抗癌治疗剂
CN110300761A (zh) * 2016-12-15 2019-10-01 国家生物技术研究所公司 抗pcna单克隆抗体及其用途

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101384618A (zh) * 2006-02-17 2009-03-11 印第安纳大学研究及科技有限公司 癌中capcna蛋白-蛋白相互作用的肽基抑制
WO2008036929A2 (en) * 2006-09-21 2008-03-27 Alnylam Pharmaceuticals, Inc. Complex for transferring an anionic substance into a cell
GB0803352D0 (en) * 2008-02-22 2008-04-02 Ntnu Technology Transfer As Oligopeptidic compounds and uses thereof
AU2009273873A1 (en) * 2008-07-24 2010-01-28 Indiana University Research And Technology Corporation Cancer peptide therapeutics
FR2942798B1 (fr) * 2009-03-05 2011-04-08 Centre Nat Rech Scient Peptides utilisables pour le traitement de la leucemie lymphoide chronique
US20120195978A1 (en) * 2009-10-07 2012-08-02 Indiana University Research And Technology Corpora Capcna peptide therapeutics for cancer
US20130059773A1 (en) * 2010-02-24 2013-03-07 Veronique Witko-Sarsat Compounds for the treatment of inflammation and neutropenia
JP2013522613A (ja) * 2010-03-18 2013-06-13 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 化学療法に対する応答性を予測するための方法
WO2013127829A1 (en) 2012-02-27 2013-09-06 Universitat De Barcelona Protease-resistant compounds useful as shuttles through the blood-brain barrier and shuttle-cargo constructs
GB201214007D0 (en) * 2012-08-07 2012-09-19 Scancell Ltd Anti-tumour immune responses to modified self-epitopes
GB201815041D0 (en) 2018-09-14 2018-10-31 Scancell Ltd Epitopes

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5935797A (en) 1994-06-16 1999-08-10 Stanford University Interaction of MHC Class II proteins with members of the PCNA family of proteins
GB9509557D0 (en) 1995-05-11 1995-07-05 Univ Dundee PCNA binding substance
WO1999065515A2 (en) * 1998-06-15 1999-12-23 Arch Development Corporation Combination of radiotherapy and anti-angiogenic factors
US7294471B2 (en) 2002-02-27 2007-11-13 Cskeys, Llc Method for purifying cancer-specific proliferating cell nuclear antigen
EA200702361A1 (ru) 2005-04-27 2008-04-28 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн АНТИТЕЛА ПРОТИВ csPCNA ИЗОФОРМЫ И ИХ ПРИМЕНЕНИЕ
CN101258161A (zh) 2005-06-27 2008-09-03 印第安纳大学研究及科技有限公司 csPCNA同种型修饰及其用途
CN101384618A (zh) * 2006-02-17 2009-03-11 印第安纳大学研究及科技有限公司 癌中capcna蛋白-蛋白相互作用的肽基抑制

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107404876A (zh) * 2015-04-10 2017-11-28 雷尔有限责任公司 抗癌治疗剂
CN110300761A (zh) * 2016-12-15 2019-10-01 国家生物技术研究所公司 抗pcna单克隆抗体及其用途
CN110300761B (zh) * 2016-12-15 2023-05-09 国家生物技术研究所公司 抗pcna单克隆抗体及其用途

Also Published As

Publication number Publication date
WO2007098415A2 (en) 2007-08-30
EP1989225A2 (en) 2008-11-12
US20160304559A1 (en) 2016-10-20
US8653039B2 (en) 2014-02-18
CA2638866A1 (en) 2007-08-30
US9187526B2 (en) 2015-11-17
US20090232882A1 (en) 2009-09-17
BRPI0707948A2 (pt) 2011-05-17
AU2007217037A1 (en) 2007-08-30
WO2007098415A3 (en) 2007-12-13
EA200801847A1 (ru) 2009-02-27
CA2638866C (en) 2015-11-10
US20140296156A1 (en) 2014-10-02
JP2009527498A (ja) 2009-07-30

Similar Documents

Publication Publication Date Title
CN101384618A (zh) 癌中capcna蛋白-蛋白相互作用的肽基抑制
US8278278B2 (en) Cell proliferation reducing cancer specific PCNA peptides
Wadia et al. Transmembrane delivery of protein and peptide drugs by TAT-mediated transduction in the treatment of cancer
EP2913057B1 (en) Cancer peptide therapeutics
CN102015758A (zh) 寡肽化合物及其应用
CN102105487A (zh) 靶向crkl的肽
CN114026114A (zh) 用于治疗再灌注损伤的bnip3肽
Puszko et al. Urea moiety as amide bond mimetic in peptide-like inhibitors of VEGF-A165/NRP-1 complex
US9593148B2 (en) DPP8 and DPP9 peptide inhibitors
US20240368566A1 (en) Pyk2-derived peptides for inhibiting invadopodia-mediated cancer metastasis
US20140005119A1 (en) COMPOSITIONS AND METHODS FOR INHIBITING THE ACTIVITY OF P110a MUTANT PROTEINS
Bendzunas All Hydrocarbon Stapled Peptides as Allosteric Modulators of Protein-Protein Interactions
EP2578227B1 (en) Cancer therapy method
HK1214177B (en) Cancer peptide therapeutics
WO2003095484A2 (en) Polypeptides increasing p53 expression
ITRM20090232A1 (it) Peptide capace di disassemblare i complessi proteici fra la proteina p53 mutata his 273 e la proteina oncosoppressiva p73 in cellule tumorali e suoi usi in campo medico.

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20090311